Goldmoney Inc. Announces Results of 2025 Annual Meeting of ShareholdersOctober 08, 2025 7:00 AM EDT | Source: GoldMoney Inc.Tortola, British Virgin Islands--(Newsfile Corp. - October 8, 2025) - Goldmoney Inc. (TSX: XAU) (US: XAUMF) ("Goldmoney" or the "Company") is pleased to announce the results of its annual meeting of shareholders (the "Meeting"), held virtually on October 7, 2025. A total of 7,699,774 common shares, representing 60.7% of the issued and outstanding common shares of the Comp ...

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $PFE #ADCs--Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman. ...

VANCOUVER, British Columbia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Asante Gold Corporation (TSXV: ASE | GSE: ASG | OTCQX: ASGOF) (“Asante” or the “Company”) today announces that Kinross Gold Corporation (“Kinross”), the holder of a secured convertible debenture issued on August 12, 2025 (the “Convertible Debenture”), has elected to convert the entire principal amount of the Convertible Debenture, together with accrued and unpaid interest thereon, in the amount of approximately US$80 million (the “Conversion Amo ...

MONTREAL, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Stingray Group Inc. (TSX: RAY.A; RAY.B) will release its financial results for the second quarter ended September 30, 2025, on Tuesday, November 11, 2025, after the markets close. Management will hold a conference call to discuss the financial results the next day, November 12, 2025, at 10:00 a.m. Eastern Time. Details of the Conference Call Via the internet at www.corporate.stingray.com Via telephone: (+1) 800-717-1738, Montreal (+1) 514-400-3792, Toronto (+1) 28 ...

, /PRNewswire/ --Â Western Midstream Partners, LP (NYSE: WES) ("WES") and Aris Water Solutions, Inc. (NYSE: ARIS) ("Aris") jointly announced today the preliminary results of the elections made by Aris securityholders regarding the form of merger consideration (the "Merger Consideration") to be received in connection with WES's pending acquisition of Aris (the "Transaction"). As further described in (i) the Agreement and Plan of Merger, dated as of August 6, 2025, by and among WES, Aris and the other parties ...

First procedures completed and enrollment underway in Embrace Gynecology study, furthering the company's progress to expand minimally invasive treatment options to patients in the United States , /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugoâ"¢ robotic-assisted surgery (RAS) system in robotic-assisted gynecological procedures. The first procedure ...

The Bank of England says the risks of a sharp market correction have increased as stock-market valuations look stretched. ...

During the arbitration hearing, both companies present their evidence and arguments. The arbitrator reviews the case and decides that Beta Supplies must compensate Alpha Tech for the defective components. This decision is final and binding, allowing both companies to move forward without the prolonged process of a court trial.Imagine two companies, Alpha Tech and Beta Supplies, are in a dispute over a contract. Alpha Tech claims that Beta Supplies delivered faulty components that didn’t meet the agreed spec ...

MONTREAL, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Stella-Jones Inc. (TSX:SJ). Open to:Investors, analysts and all interested partiesDate:Wednesday November 5, 2025Time:10:00 AM Eastern Standard Time (EST)Live Webcast:https://meetings.lumiconnect.com/400-700-172-835Call:(+1) 800 990 2777 THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKET OPENS THE DAY OF THE CONFERENCE CALL THROUGH GLOBE NEWSWIRE. Please log on or dial in 15 minutes before the conference begins. If you are unable to attend at this time, you may ac ...

– Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital – – Preliminary Total Revenue and U.S. XPOVIO (selinexor) Net Product Revenue for the Third Quarter of 2025 Expected to be in the Range of $42 to $44 Million and Approximately $32 Million, Respectively – – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – , /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering n ...